Production (Stage)
Xilio Therapeutics, Inc.
XLO
$0.8838
-$0.0132-1.47%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 69.95% | -23.82% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 69.95% | -23.82% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 69.95% | -23.82% | |||
| SG&A Expenses | 30.66% | 3.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.30% | -10.04% | |||
| Operating Income | -1.63% | 7.93% | |||
| Income Before Tax | -1.31% | 6.61% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1.31% | 6.61% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1.31% | 6.61% | |||
| EBIT | -1.63% | 7.93% | |||
| EBITDA | -0.75% | 8.10% | |||
| EPS Basic | 12.25% | 8.37% | |||
| Normalized Basic EPS | 12.25% | 8.66% | |||
| EPS Diluted | 12.25% | 8.37% | |||
| Normalized Diluted EPS | 12.25% | 8.66% | |||
| Average Basic Shares Outstanding | 15.50% | 1.91% | |||
| Average Diluted Shares Outstanding | 15.50% | 1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||